Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Phosphagenics Limited

Market Cap 57.46M 40.28M 35.12M 32.53M 30.45M 57.11M 3.8B 386M 150M 1.87B 151M 148M 6.5B P/E 2024
-2.5x
P/E 2025 -6.43x
Enterprise Value 52.81M 37.02M 32.28M 29.9M 27.99M 52.49M 3.49B 355M 137M 1.72B 139M 136M 5.97B EV / Sales 2024
5.85x
EV / Sales 2025 23x
Free-Float
75.85%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer - 2020-04-30
Chief Operating Officer - 2020-04-30
Corporate Secretary - 2026-04-30
Director TitleAgeSince
Director/Board Member - 2015-04-12
Chairman - 2018-12-31
Director/Board Member 59 2024-04-25
Change 5-day change 1-year change 3-year change Capi.($)
-14.29%-14.29% - - 40.28M
+0.07%-2.48%+42.91%+140.63% 980B
+0.91%-2.53%+51.80%+38.69% 550B
+5.57%+2.54%+23.65%+65.36% 382B
-0.27%-3.09%+23.33%+16.78% 316B
+0.29%+0.46%+27.26%+14.32% 272B
+1.34%-0.43%+25.89%+32.91% 268B
+2.05%+4.13%-34.01%-45.23% 199B
+1.30%-2.42%+25.54%+48.93% 182B
0.00%-0.45%+16.53%+58.42% 154B
Average -0.29%-2.70%+22.55%+41.20% 366.93B
Weighted average by Cap. +1.14%-3.50%+30.80%+63.88%

Financials

2024 2025
Net sales 1.13M 794K 692K 641K 600K 1.13M 74.93M 7.61M 2.95M 36.88M 2.98M 2.92M 128M 1.24M 868K 757K 701K 656K 1.23M 81.88M 8.31M 3.22M 40.3M 3.26M 3.19M 140M
Net income -3.12M -2.19M -1.91M -1.77M -1.65M -3.1M -207M -20.97M -8.13M -102M -8.22M -8.04M -353M -4.42M -3.1M -2.7M -2.5M -2.34M -4.39M -292M -29.66M -11.5M -144M -11.62M -11.37M -499M
Net Debt -1.3M -910K -793K -735K -688K -1.29M -85.86M -8.72M -3.38M -42.26M -3.42M -3.34M -147M -4.65M -3.26M -2.84M -2.63M -2.46M -4.62M -308M -31.23M -12.1M -151M -12.24M -11.97M -526M
Logo Phosphagenics Limited
Avecho Biotechnology Limited is an Australia-based biopharmaceutical company. The Company develops and commercializes human and animal health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM). TPM is derived from Vitamin E using proprietary and patented processes. The Company's segments include Production and Human Health. The Production segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health portfolio covers delivery of pharmaceutical products through gels, injectables and patches, including conduct of research and development activities. The Company's products pipeline includes Weaner Pig Starter TPM Premix, Poultry TPM Premix, Dairy TPM Premix, Daptomycin, Propofol, Veterinary Applications, among others. Its TPM products are commercialized under license: Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.
Employees
-
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!